Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 sessions: 1 to 25 of 77
Oral Abstract Session 01: Location, Location, Location: Mucosal Mediators of Risk
Role of Epithelial Cells and Fibroblasts From the Female Reproductive Tract in TFV and TAF Protection of CD4+ T Cells from HIV Infection
Charles Wira
Geisel School of Medicine at Dartmouth, United States
Optical Tissue Imaging and Spectroscopic Measurement of Spatiotemporal Tenofovir Distribution, Partitioning and Diffusivity in Vaginal and Rectal Mucosa
Oranat Chuchuen
Khon Kaen University, Faculty of Engineering, Thailand
Transplanted Human Vaginal Microbiomes Alter HIV-1 Infection and Tenofovir Efficacy in Colonized Vaginal Epithelial Multilayer Cultures
Richard Pyles
University of Texas Medical Branch, United States
Impact of Vaginal Bacteria Communities on Antiretroviral-based PrEP Drug Metabolism
Ryan Cheu
University of Washington, United States
Hormonal Contraception Induced Changes to the Female Genital Microbiota in South African Adolescents: A Randomized, Crossover Trial
Christina Balle
University of Cape Town, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, South Africa
Reducing Inflammation as a Novel HIV Prevention Approach: Aspirin Reduces Inflammation and HIV Target Cells at the Female Genital Tract
Keith R Fowke
University of Manitoba, Canada
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 02: Immunity in Human Vaccine Trials
T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines (MVA HIV-B; LIPO-5; GTU-MultiHIV B) - ANRS/INSERM VRI01 Trial
Jean-Daniel Lelièvre
Vaccine Research Institute/VRI, Hôpital Henri Mondor, France
Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial
Gregory Wilson
Vanderbilt University Medical Center, United States
V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa
Xiaoying Shen
Duke Human Vaccine Institute, United States
DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost
Zoe Moodie
Fred Hutchinson Cancer Research Center, United States
Vaccine-induced Gene Signature Correlates With Protection Against Acquisition in Three Independent Vaccine Efficacy Trials Including RV144
Rasmi Thomas
US Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, United States
Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens
Daniel J. Stieh
Janssen Vaccines & Prevention B.V., Netherlands
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 03: Structure and Maturation of bNAbs
Induction and Maturation of HIV-1 Fusion Peptide-directed Broadly Neutralizing Antibodies in Rhesus Macaques by Vaccination
Peter D. Kwong
Vaccine Research Center, United States
Identification of Near Pan-neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses
Mohammad Sajadi
Institute of Human Virology, School of Medicine, University of Maryland, United States
Structural Basis for Germline VRC01 Antibody Recognition of a Glycosylated HIV-1 Envelope CD4-binding Site
Marie Pancera
Fred Hutchinson Cancer Research Center, United States
Fast and Focused Maturation of VH1-2-restricted HIV-env CD4-binding Site Targeting bNAbs
Elise Landais
International AIDS Vaccine Initiative (IAVI), United States
Somatic hypermutation to counter a rare viral immunotype drove off-track antibodies in the CAP256-VRC26 V2-directed bNAb lineage
David Sacks
National Institute for Communicable Diseases, National Health Laboratory Service, South Africa
New SHIV Models of bNAb Elicitation and Env-Ab Coevolution
Hui Li
University of Pennsylvania, United States
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 04: Entry Into the PrEP Continuum
Tracking Global Oral PrEP Provision: The Who, What, Where of Oral PrEP
Laura Fitch
AVAC, United States
Sexual Health Goal Congruence and PrEP Adoption Among Gay and Bisexual Men in Primary Partnerships
Kristi Gamarel
University of Michigan School of Public Health, United States
Characterization of Early Adopters in a National Oral Pre-exposure Prophylaxis (PrEP) Scale-up Program in Kenya
Daniel Were
Jhpiego, Kenya
“So That I Don't Get Infected Even If I Have Sex With Someone Who Is Positive:” Factors Influencing PrEP Uptake Among Young Women in Kenya
Nicholas Thuo
Partners in Health Research and Development, Kenya
HIV-related Risks and Interest in Pre-exposure Prophylaxis (PrEP) Among Transgender Respondents of the Community-based Survey Flash! PrEP in Europe
Rosemary M. Delabre
Coalition PLUS, Community-based Research Laboratory, France
Substantial Gaps in the PrEP Continuum Among Transwomen Compared With MSM in San Francisco
Albert Liu
San Francisco Department of Public Health, United States
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 05: If I Choose, Will I Use? Products, People and Preferences
Acceptability of Long-acting Injectable Cabotegravir (CAB LA) in HIV-uninfected Individuals: HPTN 077
Elizabeth (Betsy) Tolley
FHI 360, United States
Partners, Peers and Rumours as Influencers of Use and Attitudes Towards the Dapivirine Vaginal Ring: Qualitative Data From The Ring Study (IPM 027)
Cecilia Milford
MatCH Research Unit (MRU), University of the Witwatersrand, South Africa
Testing Objective Markers of Placebo Vaginal Product Adherence in the Field
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Preference and Choice of Four Vaginal HIV Prevention Placebo Dosage Forms Among Young African Women: Results of the Quatro Randomized Crossover Trial
Elizabeth Montgomery
RTI International, United States
Attribute Preferences for Long-acting Pre-exposure Prophylaxis (PrEP): Results of a Discrete Choice Experiment With South African Youth
Alexandra Minnis
RTI International, United States
UChoose: An Adolescent Study of HIV Prevention Choice in Cape Town, South Africa
Katherine Gill
Desmond Tutu HIV Foundation, South Africa
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 06: Mucosal Models of Prevention
Combination of MUC5AC and MUC2 Enhances Antibody Neutralization Potency Against HIV-1 Infection
Arangassery Rosemary Bastian
Northwestern University, United States
Neutrophil Extracellular Traps Represent a Novel Mechanism for HIV Prevention in the Female Genital Tract
Marta Rodriguez-Garcia
Geisel School of Medicine at Dartmouth, United States
Select V2 Loop Antibodies Inhibit gp120 Binding to Integrin a4ß7
Sakaorat Lertjuthaporn
Faculty of Medicine Siriraj Hospital, Thailand
Investigating the Interactions Between HIV and a New Epithelial Target Cell in Human Genital Tissue
Jake Rhodes
Westmead Institute for Medical Research, Australia
Live Imaging of HIV-1 Transfer Across T-cell Virological Synapse to Epithelial Cells That Promotes Stromal Macrophage Infection
Morgane Bomsel
Institut Cochin CNRS UMR8104, France
Fca-receptor I Expression by Stratified Squamous Epithelia: Implications for IgA-associated Immune Function in the Human Lower Genital Tract
Kadryn Kadasia
Boston University School of Medicine, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 07: Understanding Protection Against HIV From the T Cell Perspective
Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106)
Nicole Frahm
Fred Hutchinson Cancer Research Center, United States
Gag and Env Conserved Element DNA Vaccines Elicit Cytotoxic Responses Targeting Subdominant Epitopes Able to Recognize Infected Cells in Macaques
Barbara K. Felber
National Cancer Institute at Frederick, United States
Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth of HIV in the Context of a CD8 T-cell Mediated HIV Response
Jonathan Hare
International AIDS Vaccine Initiative (IAVI), United Kingdom
Structure-based Network Analysis of HIV-1 Defines Protective CD8+ T Cell Epitopes Across Diverse HLA: Implications for Global Immunogen Design
Gaurav Gaiha
Ragon Institute of MGH, MIT & Harvard, United States
CD8+ T Cells Do Not Control SIV Replication During ART or Viral Relapse After ART Withdrawal
Afam Okoye
Oregon Health & Science University, United States
CD8 T Cells Responding to Adapted Epitopes Are Enriched in Chronic HIV Infection and Induce Dendritic Cell Maturation with Enhanced CD4 Infection
Kai Qin
University of Alabama at Birmingham, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 08: bNAbs for Prevention
Combination of HIV-1 Antibodies 3BNC117 and 10-1074 Delays Viral Rebound During Treatment Interruption
Pilar Mendoza
Rockefeller University, United States
SHIV162P3 Transmission by Semen Leukocytes Is Efficiently Inhibited by a Combination of Broad Neutralizing Antibodies
Karunasinee Suphaphiphat
CEA, France
Broadly Neutralizing Antibodies Provide Potent Dose-dependent Protection to Rhesus Macaques Against Mucosal SHIV Challenge
Amarendra Pegu
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
VRC01 Pharmacokinetics at Mucosal Sites in HIV-infected and Healthy Adults
Madhu SP Prabhakaran
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
Safety and Pharmacokinetics of Multiple Doses of a Potent Anti-HIV Monoclonal Antibody, VRC01, in HIV-exposed Newborns
Coleen Cunningham
Duke, United States
Imaging the Distribution of I.V.-injected VRC01 and VRC01-LS in the In Vivo Rhesus Macaque Model
Ann M. Carias
Northwestern University, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 09: Translating Immunity From Pre-clinical Animal Models to Humans
Co-crystal Structure of SIVmac239 gp120 with rhCD4 and Neutralizing Antibody ITS90.03 Reveals Similar Sites of Vulnerability Between HIV-1 and SIV Env
Jason Gorman
NIH/NIAID/VRC, United States
Native HIV-1 Env Circulating During the Development of Breadth in Human Subjects Elicits Tier 2 Heterologous Neutralizing Monoclonal Antibodies in NHP
Ann Hessell
Oregon Health and Science University, United States
Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies
Wilton Bryan Williams
Duke University, United States
Tight Control of SHIV BaL.P4 Challenge in Rhesus Macaques Co-immunized With DNA and Protein HIV Vaccine Regimen
Miroslaw K. Gorny
New York University School of Medicine, Department of Pathology, United States
Tracking Cy5-conjugated VRC01 Following IV Injection in the Rhesus Macaque Reveals That Tissue Distribution Can Take 1 Week to Achieve Steady State
Jeffrey Schneider
Northwestern University, United States
A Meta-analysis to Evaluate the Relationship Between Serum Antibody Neutralizing Titer and Protection Against SHIV Challenge in Nonhuman Primates
Ying Huang
Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 10: Key to the Response: Populations, Partners and Prevention
Male Partners of Adolescent Girls and Young Women (AGYW) in Durban, South Africa: How High Is Their HIV Risk and What Groups Are Most at Risk?
Julie Pulerwitz
Population Council, United States
Help-seeking Behavior of Women Reporting Intimate Partner Violence in Mwanza, Tanzania, and Its Implications for HIV: Findings From the MAISHA Study
Sheila Harvey
London School of Hygiene & Tropical Medicine, United Kingdom
Undercurrents of Sex Work: Characteristics and Experiences of Female Sex Workers in Kisumu, Kenya
Kawango Agot
Impact Research & Development Organization, Kenya
HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075 Cohort Study
Theo G.M. Sandfort
New York State Psychiatric Institute, United States
Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use
Erin C Wilson
San Francisco Department of Public Health, United States
An Integrated Intervention to Increase ART and MAT Reduces Mortality Among PWID: Results From the HPTN 074 Randomized Trial
Kostyantyn Dumchev
Ukrainian Institute on Public Health Policy, Ukraine
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 11: Novel Vaccine Strategies
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to an HIV-1 Clade C Envelope Vaccine
Robin Shattock
Imperial College, United Kingdom
Fusion Peptide-directed Antibodies Elicited in Immunized Rhesus Macaques Neutralized 59% of 208 Wildtype HIV-1 Strains
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
Vaccination of Rabbits and Macaques With V1V2-scaffold Immunogens Induces V1V2-specific Antibody Responses With Antiviral Functions
Svenja Weiss
Icahn School of Medicine at Mount Sinai, United States
Immune Control of SHIV Infection in Rhesus Macaques by PD-1-based Vaccine
Yik Chun Wong
AIDS Institute, The University of Hong Kong, Hong Kong
Vaccine-elicited Cross-neutralizing HIV Antibodies (bNAbs) to Two Env Sites of Vulnerability Following Heterologous NFL Trimer Liposome Prime: Boosting
Richard Wyatt
IAVI Neutralizing Antibody Center at Scripps, United States
Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation
Srilatha Edupuganti
Emory University, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 12: Contraception and HIV Risk: Still Between a Rock and a Hard Place
MPA, Used in Injectable Contraception, Increases HIV-1 Replication ex vivo by a Different Mechanism Compared to Luteal Phase Progesterone Levels
Chanel Avenant
University of Cape Town, South Africa
Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy
Sharon Achilles
University of Pittsburgh, United States
Increased CCR5 Levels Result in Increased R5-HIV Replication by Medroxyprogesterone Acetate, Unlike Norethisterone, via the Glucocorticoid Receptor
Janet Hapgood
University of Cape Town, South Africa
Effect of Depot-medroxyprogesterone Acetate on T Cell Expression of Immunosuppressive Markers, PD-1 and CTLA-4 in HIV-negative Women
Taguma. A Matubu
University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Zimbabwe
Successful Use of Safer Conception Strategies Resulting in High Pregnancy Rates and no HIV Transmissions Among Kenyan HIV-discordant Couples
Renee Heffron
University of Washington, United States
Risk of HIV-1 Acquisition Among South African Women Using a Variety of Contraceptive Methods in a Prospective Study
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, South Africa
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 13: Virus Control: Therapeutic Interventions
Setting the Stage for Meaningful Community Engagement and Participation in HIV Cure-related Research: Lessons Learned From the HIV Prevention Field
Melissa Hermerding
Forum for Collaborative Research, University of California, Berkeley, School of Public Health, United States
A Novel Approach to Inhibit CD4 Exhaustion: Results of a Placebo-controlled Phase II Study of a gp41 Peptide Vaccine in HIV-1 Patients Under ART
Behazine Combabière
CIMI-Paris, France
DNA-GTU/LIPO-5 Vaccine Followed by Supervised Treatment Interruption (STI) in a Therapeutic HIV Phase II Randomized Trial: VRI02 ANRS 149 LIGHT
Christine Lacabaratz
Vaccine Research Institute/VRI, France
Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV-PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected Macaques
Maria Blasi
Duke University Medical Center, United States
Long-term Delivery of Anti-HIV Monoclonal Antibodies
Jose M. Martinez-Navio
University of Miami - Miller School of Medicine, United States
Tissue Viral Seeding Drives SHIV Pathogenesis in Infant Macaques and Is Reduced by Early bNAb Therapy
Ann Hessell
Oregon Health and Science University, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 14: Antibody Functions Beyond Neutralization
HIV gp120 V2 Mimics IgSF Domain 1 of MAdCAM, the Natural Ligand of Integrin a4ß7
James Arthos
NIAID, NIH, United States
IgG3 Hinge Length Enhances Neutralization Potency and Fc Effector Function of an HIV V2-specific Broadly Neutralizing Antibody
Simone Irene Richardson
Centre for HIV & STIs, National Institute for Communicable Diseases, South Africa
Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute Subtype C Envs: Implications for Prevention and Treatment of HIV-1 Infection
Dieter Mielke
Duke University, United States
Structural Characterization of Rhesus Macaque Fc Domains of IgG1-4 and the Fc?RIIIa1-IgG1Fc Complex
William Tolbert
Institute of Human Virology, University of Maryland, School of Medicine, United States
IgA Inhibits HIV-specific Antibody-dependent Neutrophil Phagocytosis
Matthew Worley
The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia
Tight Control of SHIVBaL in Rhesus Macaques Immunized With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p Antibodies
Susan Zolla-Pazner
Icahn School of Medicine at Mount Sinai, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 15: New ARVs for Prevention
Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques
James Cummins
Division of AIDS, NIAID, NIH, United States
Efficacy of UAMC01398 Gel Formulation in NHP Model of HIV Vaginal Transmission
Delphine Desjardin
CEA Université Paris Sud, Inserm u1184, IDMIT Department, France
Dose-ranging Pharmacokinetic Assessment of Vaginally Administered EVG/TAF Inserts in Macaques for PrEP
Charles Dobard
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States
HIV Prevention in Healthy Women: Safety and Pharmacokinetics of a Potential New Tenofovir Alafenamide Fumarate (TAF)-based Oral PrEP Regimen
Jill Schwartz
CONRAD Eastern Virginia Medical School, United States
Cabotegravir (CAB) Long-acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-infected Adults
Susan Ford
PAREXEL International, United States
Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 16: Tickling the Germline
Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for Broadly Neutralizing Reactivity With a Designed Immunogen
Kevin Wiehe
Duke University, United States
Carbohydrate Mimicry for Eliciting Oligomannose-targeting Neutralizing Antibodies to HIV-1
Ralph Pantophlet
Simon Fraser University, Canada
Vaccine Induction of VRC01-class Neutralizing Antibodies in a Knock-in Mouse Model
Xuejun Chen
Vaccine Research Center/NIAID/NIH, United States
Engineering HIV Immunogens to Elicit IOMA-like Antibodies Targeting the CD4 Binding Site
Harry Gristick
Caltech, United States
Phenotypic Deficits in the HIV-1 Envelope Are Associated With the Maturation of a V2-directed Broadly Neutralizing Antibody Lineage
Lucia Reh
University of Zurich, Switzerland
Chimpanzee SIV Envelope-derived Trimer Guides an Immunofocused HIV Cross-neutralizing Ab Response in V2-apex bnAb UCA Expressing Knock-in Mice
Raiees Andrabi
The Scripps Research Institute, United States
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 17: Factors Influencing Viral Transmission and Spread
HLA Pre-adaptation in Gag Influences Viral Evolution in the New Host
Daniela Monaco
Emory University, United States
Treatment of Schistosoma mansoni Infection in Ugandan Women Reduces HIV Entry Into Cervical CD4 T Cells and Induces Type I Interferon Pathways
Rupert Kaul
University of Toronto, Canada
The Eclipse Phase Lasted a Week in HIV-1-infected Adults in East Africa and Thailand
Morgane Rolland
MHRP | HJF, United States
Infection With Multiple Transmitted/Founder (TF) HIV-1 Viruses Impacts Peak VL and HIV-1 Pathogenesis
Gladys Macharia
IAVI Human immunology Lab, Imperial College London, United Kingdom
Localization of Infection in Neonatal Rhesus Macaques After Oral Viral Challenge
Roslyn A. Taylor
Northwestern University, United States
Gp41 Ectodomain-specific IgG is Associated with Increased Vertical HIV-1 Transmission
Nicole Naiman
Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 18: Opinion 360: Meaningful Engagement From Research to Roll Out
Beneficial Impacts Related to Participating in an International HIV Prevention Trial Involving People Who Inject Drugs
Jeremy Sugarman
John Hopkins, United States
Standardized Metrics Can Reveal Region-specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials
Gail Broder
Fred Hutchinson Cancer Research Center, United States
Ethical Considerations for Involving Adolescents Aged 16-17 in HIV Prevention Clinical Trials: Community Perspectives from Uganda
Rita Nakalega
Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration, Uganda
The Luxuriant Future of Microbicides: Planning for Success
Marc-André LeBlanc
HIV Prevention Advocate, Canada
Planning for PrEP: Facilitating Collaborative Cross-country Learning
Neeraja Bhavaraju
FSG, United States
Princess PrEP Program: A Successful Key Population-led PrEP Model in Thailand Forming Through Meaningful Participation of Key Populations
Nittaya Phanuphak
Thai Red Cross AIDS Research Centre, Thailand
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 19: Stay With Me: Retention on PrEP
PrEP Uptake and Retention Among Men and Women Receiving PrEP Integrated in Public Health HIV Care Clinic Settings
Kenneth Mugwanya
University of Washington, United States
Examining PrEP Interruptions in a Safety-net Primary Care Network: Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP Services
Matthew Spinelli
University of California, San Francisco, United States
Early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African Adolescent Girls and Young Women (AGYW) from Kenya and South Africa
Elzette Rousseau-Jemwa
Desmond Tutu HIV Foundation, South Africa
Intimate Partner Violence and Early PrEP Adherence Among Adolescent Girls and Young Women in Cape Town, South Africa: A Longitudinal Analysis
Sarah T. Roberts
RTI International, United States
Early Antiretroviral Therapy and Daily Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin: A Demonstration Study
Michel Alary
CHU de Québec, Canada
Trends in Engagement in the HIV Prevention and the Care Cascade among Young Women who Sell Sex in Zimbabwe
Sue Napierala
RTI International, United States
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 20: Into the Future With Delivery Technologies
Nanoparticles-in-thermosensitive Enemas as Potential Vehicles for Microbicide Development
Mélanie Melo
i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal
Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)
Ariane van der Straten
RTI International, United States
Tenofovir Douche for PrEP: On-demand, Behaviorally-congruent Douche Rapidly Achieves Colon Tissue Concentration Targets (DREAM 01 Study)
Ethel Weld
Johns Hopkins University, United States
Self-administered Griffithsin and Carrageenan Containing Microbicide Fast-dissolving Insert as Pre-exposure Prophylaxis Against HIV and HPV Infections
Thomas Zydowsky
Population Council, United States
Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose Intravaginal Rings for Prevention of HIV and Unintended Pregnancy
S. Rahima Benhabbour
University of North Carolina, Chapel Hill, United States
The Dapivirine and Levonorgestrel MPT Ring: Understanding the Levonorgestrel Binding Reaction with Silicone Elastomer
Karl Malcolm
Queen's University Belfast, United Kingdom
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 21: Linking Arms in Defense: Innate, Cellular and Humoral
Vaccine-induced Activation of Inflammasome in Classical Monocytes and Th2 Cell Responses Correlates With Decreased Risk of SIVmac251 Acquisition
Monica Vaccari
NCI, NIH, United States
Soluble Immune Activation Biomarkers Predict Accelerated Viral Rebound During Treatment Interruption in Fiebig I-treated Individuals
Bonnie M. Slike
US Military HIV Research Program/WRAIR, United States
Recombinant MVA Prime Elicits Neutralizing Antibody Responses by Inducing Antigen-specific B Cells in the Germinal Center
Sampa Santra
Beth Israel Deaconess Medical Center, Harvard Medical School, United States
Targeting HIV gp140 Env to Human Langerhans Cells Drives Tfh Differentiation and Antibody Responses
Jérôme Kervevan
Inserm U955 - Institut Mondor de Recherche Biomédicale, UPEC, France
Broadly Neutralizing Antibodies in Children Correlate With Increased HIV-specific T-follicular Helper and Regulatory Cells Within Germinal Centers
Julia Roider
Ludwig-Maximilians-University, Germany
The Impact of Vaccination on SIV Evolution Following Break-through Infection
Kathryn Foulds
VRC/NIAID/NIH, United States
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 22: Antibody Virus Tango
Targeted Viral Selection Is Associated With the Development of HIV Broadly Neutralizing Antibodies
Batsirai Mabvakure
Center for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa
Next-generation Sequencing Delineates the Developmental Pathway of Fusion Peptide-directed Broadly Neutralizing Antibody N123-VRC34.01
Chen-Hsiang Shen
Vaccine Research Center, NIAID, NIH, United States
Early Antibodies Against the Transmitted/Founder HIV-1 Envelope gp120 Are Dominated by the Immunoglobulin Heavy Chain Germline VH1-69
S. Abigail Smith
Emory University, United States
“Designer” SHIVs Elicit V2 bNAbs in Rhesus Macaques
Ryan S. Roark
University of Pennsylvania, United States
eCD4-Ig Is More Difficult to Escape Than Broadly Neutralizing Antibodies
Christoph H. Fellinger
The Scripps Research Institute, United States
Defining and Characterizing the ‘Escapability' of Potent Broadly Neutralizing Antibodies Against HIV in Humanized Mice
Cailin Deal
The Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 23: Great Expectations: The Impact of PrEP
HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies
Jared Baeten
University of Washington, United States
Sensitive Next-generation Sequencing of HIV-1 From Seroconverters in the MTN-020/ASPIRE Dapivirine Vaginal Ring Study
Urvi Parikh
University of Pittsburgh, United States
Transgender Women on Estrogen Have Significantly Lower Tenofovir/Emtricitabine Concentrations During Directly Observed Dosing When Compared to Cis Men
Craig Hendrix
Johns Hopkins University, United States
Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017
Kenneth H. Mayer
Fenway Health, United States
Mathematical Modeling to Evaluate the Impact and Cost-effectiveness of Oral Pre-exposure Prophylaxis for HIV Prevention in Uganda
Katharine Kripke
Avenir Health, Project SOAR, United States
Potential Impact of Increased ART and PrEP Coverage on the HIV Epidemic Among MSM in Atlanta: Mathematical Modelling for HPTN 078
Kate M. Mitchell
Imperial College London, United Kingdom
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 01: Antibody Epitopes: Connecting the Dots
A Prominent Site of Antibody Vulnerability on HIV Env Incorporates the CCR5 Coreceptor Site and Its Camouflaging Glycans
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject
Nicole A. Doria-Rose
Vaccine Research Center, NIAID, NIH, United States
Persistence of an HIV Broadly Neutralizing Antibody Lineage Despite Complete Neutralization Escape
Jinal N Bhiman
National Institute for Communicable Diseases of the National Health Laboratory Services, South Africa
Viral Escape from HIV Broadly Neutralizing Antibodies Is Slower and More Complex than for Early Strain-specific Neutralizing Antibodies
Colin Anthony
University of Cape Town, South Africa
The Anti-gp120 mAb CH58 Recognizes a Not-fully-processed Form of Surface-expressed Env
Jason Yolitz
NIAID, NIH, United States
Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 02: Crossing the Border: Mechanisms of Mucosal Transmission
Defining HIV/SIV Infection after Rectal Challenge in Rhesus Macaque Model Using Dual Reporter System
Danijela Maric
Northwestern University, United States
Broadly Neutralizing Antibodies Can Prevent HIV Infection in Foreskin Ex-vivo Explant Infection Models
Maria Lemos
Fred Hutchinson Cancer Research Center, United States
In Vivo Analysis of Fluorescently Tagged HIV-specific and Non-specific Antibodies in Non-human Primates
Ann M. Carias
Northwestern University, United States
HIV Susceptibility in CD4+ T Cells Derived from the Inner Versus Outer Foreskin
Ronald Galiwango
University of Toronto, Canada
Intestinal Dendritic Cells and Macrophages Differentially Affect HIV-1 Transmission Across the Intestinal Mucosa
Mariangela Cavarelli
CEA, France
Levels of Immune Activation in Cervical Cells, Rectal Cells and PBMCs Isolated from a Kenyan Women Cohort at Low-risk of HIV Acquisition
Catia Perciani
University of Toronto, Canada
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 sessions: 1 to 25 of 77